EGFR and cancer: The discovery of the connection between mutant epidermal growth factor receptor (EGFR) and cancer cell response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) that led to development of EGFR-targeted therapy has revolutionized the treatment of NSCLC.